In Brief: Rhone-Poulenc Rorer's Nasacort AQ
Executive Summary
Rhone-Poulenc Rorer's Nasacort AQ: Water-based formulation of Nasacort for treatment of allergic rhinitis will be available in the end of June following May 20 FDA clearance, company announces. The CFC propellant-free aqueous microcrystalline suspension is indicated for once-daily use in children over age 12 and adults. Also, Nasacort was approved in children over age six, recommended at the same starting dose of 220 mcg per day given as two sprays in each nostril...